Louise Atkinson lost two stone in eight months on the GLP‑1 drug Mounjaro, but then the weight‑loss curve flattened. She combed through Facebook groups and medical advice to pinpoint why the plateau occurs and what practical steps can revive progress.

Louise Atkinson’s two‑stone loss and the MJ plateau

According to the original report, Atkinson entered the program a year ago, dropped roughly 28 kg, and now finds herself a few pouds shy of her goal. The plateau, the author notes, is a common complaint among users paying £180‑£300 a month for the medication. Medics explain that the body adapts to appetite suppression and slower gastric emptying, while old eating habits creep back in.

Switching injection sites to revive GLP‑1 absorption

One tip highlighted is rotating injection sites. the source explains that injecting into fatty tissue slows drug absorption, allowing the GLP‑1 to bind to blood proteins and linger for days. In contrast,muscle injections can cause faster, less predictable uptake. as users lose fat, previously safe sites like the thigh or upper arm may become more muscular, reducing efficacy. Moving the injection spot each week,especially staying near the abdoomen, can protect tissue and sustain drug levels.

Protein targets that may reignite fat loss

Rob Hobson, a consultant nutritionist cited in the article, recommends 1.2‑1.6 g of protein per kilogram of target body weight daily – roughly 25‑30 g per meal. He argues that adequate protein supports muscle maintenance, boosts metabolism and curbs cravings, all of which are vital when the drug’s appetite‑suppressing punch wanes. Atkinson’s own experience suggests that late‑night snacking returned once her portion sizes stayed unchanged.

Off‑label dose tweaks and their cost implications

The report describes a DIY method of increasing the dose without buying a pricier pen. By counting the clicks on a 5 mg pen,users can deliver 3‑4 mg doses, spreading the extra cost over six or seven weeks. this practice is off‑label and not endorsed by pharmacists, yet many report renewed weight loss. The author warns that any dose adjustment should be discussed with a prescriber.

Is the higher‑dose off‑label strategy safe?

Two specific uncertainties remain: first, whether the incremental dose truly offers a metabolic jump‑start, and second, what long‑term safety data exist for such off‑label use. The source does not provide clinical trial evidence, and it notes that pharmacists generally discourage the practice. Readers are left to weigh potential benefits against unknown risks.